Bayer Cuts Costs To Focus On Innovation And Emerging Markets

BMI Core View: Pharmaceutical sales forces will contract in developed states and expand in emerging markets. The primary cause of this trend is the declining influence of US and Western European doctors on prescribing decisions, itself due to state-imposed cost-containment measures. Accordingly, drugmakers operating in traditional markets are shifting resources from mass prescriber-level detailing to vertically-integrated, cost-benefit promotion. This business activity involves far fewer individuals and the sizes of sales teams are being

To read the full article, please choose one of the following options: